LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
K.N. Chi, Elena Castro, Gerhardt Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, A.J.P.D.S. Gomes, Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Angela Lopez‐Gitlitz, W. Kim, David Olmos (2023). LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.087.
